Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome

IMPORTANCE: In 2006, the US Food and Drug Administration (FDA) issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, but the true risk of s...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Neurol
Main Authors: Orlova, Yulia, Rizzoli, Paul, Loder, Elizabeth
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2018
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885255/
https://ncbi.nlm.nih.gov/pubmed/29482205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.5144
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares